论文部分内容阅读
目的:探讨复方鳖甲软肝片联合拉米夫定治疗慢性乙型肝炎肝纤维化的疗效。方法:选择90例慢性乙型肝炎肝纤维化的患者按治疗先后以1:1:1随机分为A、B、C组各30例,A组采用拉米夫定及复方鳖甲软肝片;B组采用拉米夫定及甘利欣胶囊;C组采用甘利欣胶囊及复合维生素或复方益肝灵片,疗程均为12月。主要观察3组患者HBV DNA阴转情况及肝纤维化指标改善情况。结果:A、B两组患者在抑制HBV DNA复制指标方面与C组比较,有非常显著的统计学差异(P<0.001),A组与B组比较也有统计学意义(P<0.05)。A、B两组治疗后肝纤维化指标改善情况均明显优于C组(P<0.01)。在治疗后A组的各项肝纤维化指标的改善也优于B组(P<0.01)。结论:复方鳖甲软肝片与拉米夫定的联合,不仅能增强抑制HBV DNA的复制作用,更能显著提高抗肝纤维化的治疗效果。
Objective: To investigate the curative effect of compound Biejia Ruangan Pian combined with lamivudine on chronic hepatitis B liver fibrosis. Methods: Ninety patients with chronic hepatitis B liver fibrosis were randomly divided into A, B and C groups according to the treatment of 1: 1: 1, 30 cases in each group. A group was treated with lamivudine and Fufang Biejia Ruangan tablets ; B group lamivudine and Gan Lixin capsule; C group using Gan Lixin capsule and compound Yiganling tablets, treatment were December. Mainly observed three groups of patients with HBV DNA negative conversion and improvement of liver fibrosis indicators. Results: There was a significant difference (P <0.001) between group A and group B in inhibiting the replication of HBV DNA compared with group C, and there was significant difference between group A and group B (P <0.05). The improvement of liver fibrosis indexes in group A and group B were better than group C (P <0.01). After treatment, the improvement of various indexes of liver fibrosis in group A was also better than that in group B (P <0.01). Conclusion: The combination of Fufang Biejia Ruangan Pian and Lamivudine can not only enhance the inhibitory effect of HBV DNA replication, but also significantly improve the therapeutic effect of anti-liver fibrosis.